Casado, MDI, Aperribay, EA, Campelo, MRG, Blanco, CM, Tain, PD, Piqueras, MMLB, Vega, ALM, Mateos, LAL, Rodriguez, JMO, Calderon, VG, Majem, M, Hernandez, AS, de la Rosa, CA, Cabellos, RA, Sureda, BM, Baret, M, Martos, JLL, Dominguez, M, Paz-Ares, L. Long-term survivors with extensive-stage small-cell lung cancer treated with first-line durvalumab plus carboplatin and etoposide: The CANTABRICO trial. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).

Rueda-Lara, A, Viñal, D, Martínez-Pérez, D, Alameda-Guijarro, M, Martin-Montalvo, G, Martínez-Recio, S, Peña-Lopez, J, Jiménez-Bou, D, Ruíz-Gutiérrez, I, García-Leal, A, Zwisler-Contreras, P, Ghanem, I, Custodio, AB, Pérez-Wert, P, Gutiérrez-Sainz, L, Palacios, ME, Feliu, J, Rodríguez-Salas, N. Analysis of tumor budding as a prognostic factor for recurrence in patients with stage II and III colon cancer. Experience in a tertiary hospital. ONCOLOGIST. 2025; 30(3)DOI:10.1093/oncolo/oyaf027. PMID:40152315. IF:4.200(Q2/3D).

Fernandez-Mañas, L, Ortiz, I, Pozas, J, Beland, C, Larkin, J, Moll-Febrer, A, González-Aguado, L, Beltran, JS, Anguera, G, Navarro, N, Rodriguez-Vida, A, Novella, SR, Sierra, M, Carrasco, A, González, NS, Yonamine, EPM, Maeso, IG, Figols, M, Alcalá, MM, Reig, O. Impact of site of metastatic involvement on IMDC classification in metastatic renal cell carcinoma patients treated with immunotherapy.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(5_SUPPL)DOI:10.1200/JCO.2025.43.5_suppl.483. PMID:. IF:41.900(Q1/1D).

Rioja, P, Passarella, C, Angel, M, Valderrama, W, Bosma, F, Anguera, G, Gomez, V, Ruiz-Granados, A, Plata, D, Laguado, MIZ, Orta-Ruiz, A, Gandur-Quiroga, MN, Bourlon, MT, Grande, E, Manneh, R, Molina-Cerrillo, J, Maroto-Rey, P, Sade, JP, Castellano, D. Impact of deferred cytoreductive nephrectomy in the era of the immunotherapy in metastatic renal cell carcinoma: A multicenter retrospective study.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(5_SUPPL)DOI:10.1200/JCO.2025.43.5_suppl.502. PMID:. IF:41.900(Q1/1D).